Cyclooxygenase-2 inhibitor-associated acute renal failure: Case report with rofecoxib and review of the literature
Cyclooxygenase-2 inhibitor-associated acute renal failure: Case report with rofecoxib and review of the literature
复制标题
DOI：
10.1592/phco.22.15.1317.33472
复制
发表时间：
2002-10-01
期刊：
影响因子：
4.1
通讯作者：
Mucksavage, JJ
中科院分区：
文献类型：
--
作者：
Morales, E;Mucksavage, JJ
环加氧酶 (COX)-2 抑制剂因其抗炎和镇痛作用而被广泛使用。 COX-2 抑制剂对肾功能产生类似于传统非甾体类抗炎药的有害影响的可能性尚未明确。直到最近，COX-1 还被认为负责肾脏前列腺素的合成。然而，COX-2也在人肾中组成型表达。临床研究报告称，服用 COX-2 抑制剂的年轻和老年缺钠志愿者的肾小球滤过率显着降低。我们描述了一位 71 岁女性的病例，她在接受 50 毫克剂量的选择性 COX-2 抑制剂罗非昔布后出现急性肾功能衰竭。
Cyclooxygenase (COX)-2 inhibitors are widely prescribed for their antiinflammatory and analgesic effects. The potential for COX-2 inhibitors to exert deleterious effects on renal function similar to those of traditional nonsteroidal antiinflammatory drugs is not well defined. Until recently, COX-1 was considered responsible for the synthesis of renal prostaglandins. However, COX-2 is also constitutively expressed in the human kidney. Clinical studies have reported a significant decrease in glomerular filtration rate in young and elderly sodium-depleted volunteers given COX-2 inhibitors. We describe the case of a 71-year-old woman who developed acute renal failure after receiving a 50-mg dose of the selective COX-2 inhibitor rofecoxib.